Publications by authors named "Madeleine Lester"
Background: Monoclonal antibodies have emerged as a leading therapeutic agent for the treatment of disease, including Alzheimer's disease. Such antibodies, however, are expensive and timely to produce and require frequent dosing regimens to ensure disease-modifying effects. Synthetic in vitro-transcribed mRNA encoding antibodies presents a promising alternative to conventional passive immunotherapy and overcomes the need to generate recombinant antibodies.
View Article and Find Full Text PDFArticle Synopsis
- Monoclonal antibodies, like lecanemab and aducanumab, have been recently approved in the USA as treatments for Alzheimer's disease, although they are costly and require frequent administration.
- Researchers are exploring synthetic messenger RNA (mRNA) as a new method to produce antibodies, potentially addressing the limitations of traditional antibody production.
- This study successfully created synthetic mRNA for a tau-specific antibody, demonstrating its effectiveness in producing functioning antibodies and targeting intracellular tau, which could benefit Alzheimer's and related diseases.